Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial
More patients treated with deucravacitinib met each of the MDA components vs placebo, along with a higher rate of MDA response, after 16 weeks of treatment.
Authors
- Miroslawa Nowak
- Lauren Hippeli
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Philip J. Mease (ORCID: https://orcid.org/0000-0002-6620-0457)
- Laura C. Coates (ORCID: https://orcid.org/0000-0002-4756-663X)
- Subhashis Banerjee (ORCID: https://orcid.org/0009-0000-1365-5207)
- Arthur Kavanaugh
- Thomas Lehman (ORCID: https://orcid.org/0000-0001-6588-4212)
Institutions
- Providence College (US)
- University of Washington (US)
- Nuffield Orthopaedic Centre (GB)
- University of California San Diego (US)
- University of Oxford (GB)
- NIHR Oxford Musculoskeletal Biomedical Research Centre (GB)
- Bristol-Myers Squibb (United States) (US)
- Swedish Medical Center (US)
- Southwestern Medical Center (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1093/rheumatology/keae580
- Citations
- 9
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.16
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Celgene